Autoimmune diseases



The prevalence of autoimmune disorders is increasing worldwide, but effective options to stop or reverse the progression of these diseases are lacking.



Animal models used to study disease mechanisms and test therapeutic strategies fail to replicate the complex biological interactions involved in autoimmune diseases.



Biological differences between human and animal immune systems limit extrapolation from animal models to patients.



Human-based models offer more efficient options to elucidate disease mechanisms and discover potential drug targets.



The use of human primary cells is of great importance to understand the genetic, molecular and cellular factors that contribute to human pathogenesis.





Insulin-producing organoids and spheroids engineered from human cells are relevant models for studying autoimmune diabetes.



Human skin slices cultured with human immune cells allow the analysis of cell-tissue interactions, immune activation, and underlying biological mechanisms.



In silico models are a valuable means of gaining new insights and testing hypotheses, particularly when used in conjunction with clinical observations and in vitro models.

Autoimmune diseases

FUTURE DEVELOPMENTS AND CHALLENGES TO BE OVERCOME



The positive trend in the use of *in vitro* models to develop new therapeutic strategies suggests a demand for advanced non-animal models to better mimic human diseases.



With appropriate development, human stem cell models will play a leading role in studying the molecular mechanisms of autoimmune diseases, and in identifying and testing new therapeutic strategies.



A better understanding of the complex network of dysfunctional interactions that lead to the development of most autoimmune diseases will allow the full exploitation of in vitro and in silico models.



The availability of donors represents a limit in the use of human primary cells.



There is a real need to enhance the development of human immune system cells, tissues and organs in vitro using integrated approaches such as tissue and body-on-chip platforms.



The establishment of a common platform to freely share in humano, in vitro and in silico data is crucial to advance the modelling of the highly complex human immune system and its disorders.